“
“Objective: Many cancer patients report cognitive changes following chemotherapy. In social psychology, there is ample evidence that psychological and physical complaints can increase with increased accessibility of relevant schemata. The accessibility of related concepts in memory may be facilitated through priming or by pre-existing this website knowledge, resulting in an increase of reported complaints. We examined whether pre-existing knowledge of chemotherapy-associated
cognitive problems and priming the ‘chemo-brain’ schema increase the reporting of cognitive complaints.
Methods: Two hundred and sixty-one breast cancer patients were interviewed about cognitive problems and other cancer-related symptoms. Preceding the interview, half of the patients were primed with an introduction letter to the study in which the occurrence of cognitive complaints and its relation with chemotherapy was explicated. The remaining patients received a neutral letter that did not mention this relationship.
Results: Patients with pre-existing
knowledge about chemotherapy-associated cognitive problems reported more cognitive complaints (M = 3.04) than patients without this knowledge (M = 2.21; p < 0.001). The priming letter increased the reporting of cognitive complaints only for patients without a history of chemotherapy (p < 0.05). All effects were independent of negative affect, age and education level.
Conclusion: Our study shows that facilitating the accessibility of concepts related to chemotherapy-associated cognitive complaints Selumetinib order directly increases the reporting of such complaints, in particular in patients
without firsthand chemotherapy experience. This increase in prevalence of cognitive complaints following a chronically or temporarily accessible ‘chemo-brain’ schema has relevant implications for clinical practice and for scientific research in this area. Copyright (C) 2008 John Wiley & Sons, Ltd.”
“Objectives: Serum bone turnover markers (sBTM) are used in clinical practice for patients undergoing postmenopausal osteoporosis therapy. The aim of this study was to systematically analyze the literature on the ability of sBTM to monitor therapy, focusing Cell Cycle inhibitor on the following 5 objectives: (1) pretreatment values and treatment choice; (2) short-term changes and clinical response; (3) sBTM effect on persistence to therapy; (4) sBTM ability to predict fracture risk after withdrawal of therapy; and (5) the prediction of serious adverse effects.
Methods: A systematic search on Medline completed manually was performed until November 2010 and was limited to postmenopausal osteoporosis and marketed therapies.
Results: Following the PRISMA statement for systematic reviews, 48 studies were selected. Baseline sBTM levels were not able to predict fracture risk reduction with either treatment.
Related posts:
- Commercially insured patients with lung cancer when compared with a matched control group
- Nutlin-3 Cancer of 19 patients on therapy.
- Two patients died (lung cancer and myocardial infarction) At mon
- Two patients died (lung cancer and myocardial infarction) At mon
- Eleven patients (55%) died, 9 patients (45%) are alive The 5 yea